Cystic fibrosis-associated liver disease: When will the future be now?

Journal of Pediatric Gastroenterology and Nutrition

Volumn 54, Issue 3, 2012, Pages 312-

  Rudnick, David A ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINA1 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

CYSTIC FIBROSIS; CYSTIC FIBROSIS ASSOCIATED LIVER DISEASE; DNA POLYMORPHISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; INCIDENCE; LIVER DISEASE; LIVER FIBROSIS; MORTALITY; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT;

BILIARY ATRESIA; CHOLESTASIS; CYSTIC FIBROSIS; GENE EXPRESSION; HUMANS; LIVER; LIVER CIRRHOSIS; TRANSCRIPTION, GENETIC;

EID: 84857785537     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182309fd0     Document Type: Note

References (9)

1. Pereira T, Lewindon P, Greer R, et al. Transcriptional basis for hepatic fibrosis in cystic fibrosis-associated liver disease. J Pediatr Gastroenterol Nutr 2012;54:328-35.
2. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002;36:1374-82. (Pubitemid 35403528)
3. Debray D, Kelly D, Houwen R, et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011;10(suppl 2):S29-36.
4. Bartlett JR, Friedman KJ, Ling SC, et al., Gene Modifier Study GroupGenetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83.
5. Arkwright PD, Pravica V, Geraghty PJ, et al. End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med 2003;167:384-9. (Pubitemid 36216420)
6. Henrion-Caude A, Flamant C, Roussey M, et al. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology 2002;36:913-7.
7. Gabolde M, Hubert D, Guilloud-Bataille M, et al. The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J Med Genet 2001;38:310-1. (Pubitemid 32433983)
8. Colombo C, Battezzati PM, Podda M, et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996;23:1484-90. (Pubitemid 26181232)
9. Cystic Fibrosis Liver Disease: Clinical Research Workshop. Bethesda, MD: National Institutes of Health. June 8-9, 2009. http://www3.niddk.nih.gov/fund/ other/cfld. Accessed January 18, 2012.